
Because zzso associated with chemotherapy and zzso can adversely affect zzso and long-term patient quality of life, can limit the dose and duration of treatment, and may be zzso specific agents designed to zzso or eliminate certain chemotherapy and zzso zzso have been zzso zzso in interpretation of the available data pertaining to the efficacy of the three United States Food and Drug zzso agents that have potential zzso and zzso zzso zzso and zzso questions about the role of these zzso agents in cancer care led to concern about the appropriate use of these zzso The American Society of Clinical Oncology sought to establish zzso clinical practice guidelines for the use of zzso zzso and zzso in patients who are not enrolled on clinical treatment zzso 

A multidisciplinary Expert Panel reviewed the clinical data regarding the activity of zzso zzso and zzso A computerized literature search was performed using zzso In addition to reports collected by individual Panel members, all articles published in the English-speaking literature from June 1997 through December 1998 were collected for review by the Panel zzso and appropriate articles were distributed to the entire Panel for zzso zzso for use, levels of evidence, and grades of recommendation were reviewed and approved by the zzso Outcomes considered in evaluating the benefit of a zzso or zzso agent included zzso of zzso and long-term zzso or zzso zzso risk of tumor protection by the agent, toxicity of the zzso agent itself, quality of life, and economic zzso To the extent that these data were available, the Panel placed the greatest value on lesser toxicity that did not carry a zzso risk of tumor zzso 

zzso zzso zzso zzso as detailed in these guidelines, is recommended to decrease the zzso of zzso zzso zzso zzso zzso There is insufficient evidence on which to base a zzso for the use of zzso to prevent zzso toxicity with zzso doses that exceed zzso zzso zzso Either zzso or forced saline zzso is recommended to decrease the zzso of zzso toxicity associated with high-dose zzso use in the stem-cell transplantation zzso zzso zzso The use of zzso is not routinely recommended for patients with zzso breast cancer who receive initial zzso zzso zzso The use of zzso may be considered for patients with zzso breast cancer who have received a cumulative dosage of 300 zzso or greater of zzso in the zzso setting and who may benefit from continued zzso zzso zzso The use of zzso in the zzso setting is not recommended outside of a clinical zzso zzso The use of zzso can be considered in adult patients who have received more than 300 zzso of zzso therapy for tumors other than breast cancer, although caution should be used in settings in which zzso therapy has been shown to improve survival because of concerns of tumor protection by zzso zzso There is insufficient evidence to make a zzso for the use of zzso in the treatment of pediatric zzso with zzso regimens, or with high-dose zzso zzso Similarly, there is insufficient evidence on which to base a zzso for the use of zzso in patients with cardiac risk factors or underlying cardiac zzso zzso Patients receiving zzso should continue to be monitored for cardiac zzso zzso zzso zzso may be considered for the reduction of zzso in patients receiving zzso zzso 

